Summary
The product Halotestin Fluoxymesterone 5 mg, manufactured by Unique Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number UN64113 exp 02/2026, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Fluoxymesterone, with a concentration of 6.64 mg per tablet, exceeding the labeled claim of 5 mg by 32.8%.
The testing process began on 18 June 2024, with the sample received on 20 June 2024, and analysis completed on 21 June 2024. While the results confirm accurate dosing, scrutiny of reseller-submitted samples is essential to ensure reliability. Resellers may select specific batches that meet high-quality standards, raising questions about product consistency across the broader market. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: Halotestin Fluoxymesterone 5 mg
- Active Ingredient: Fluoxymesterone
- Batch Number: UN64113 exp 02/2026
- Expiration Date: February 2026
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #44218
- Testing Ordered: 18 June 2024
- Sample Received: 20 June 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 5 mg (as stated on the label)
- Measured Concentration: 6.64 mg
- Accuracy: 132.8% (32.8% above the label claim)
- Variance: 32.8%
Verification Details
- Verification URL: https://janoshik.com/tests/44218_NX9XQFE17BNU
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis highlights the accuracy of the tested product but warrants careful evaluation due to its submission and funding by the reseller Opitropin.EU. Resellers often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Halotestin Fluoxymesterone 5 mg is significantly overdosed, with a measured concentration of 6.64 mg per tablet. This result reflects strong quality control for this batch but underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
